Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

II clinical trial designed to evaluate the safety and efficacy of ispinesib in the treatment of patients with chemotherapy-na? recurrent or metastatic malignant melanoma was recently completed. In Stage 1 of this two-stage clinical trial, 17 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the RECIST criteria. This trial was designed to require at least 1 confirmed partial response in 15 patients in Stage 1 in order to proceed to Stage 2. The best overall response was stable disease seen in 6 of 17 patients treated. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the second stage and therefore recruitment to Stage 2 was not opened. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscript is being prepared.

A Phase II clinical trial designed to evaluate the safety and efficacy of ispinesib for the treatment of hormone refractory prostate cancer who had failed taxane-based chemotherapy was recently completed. In Stage 1 of this two-stage clinical trial, 21 patients received ispinesib as monotherapy at 18 mg/m2 as a 1-hour intravenous infusion every 21 days. The trial s primary endpoint was objective response as determined using the RECIST criteria and a prostate-specific antigen (PSA) response of a greater than 50% decline confirmed 3 weeks later. This trial was designed to require a minimum of 1 PSA response in the first 20 evaluable patients in Stage 1 in order to proceed to Stage 2. No patient met the criteria for a PSA response and the median time to PSA or clinical progression was 9 weeks. In this clinical trial, ispinesib did not satisfy the criteria for advancement to the next stage in the clinical trial. The toxicity profile was consistent with other previously reported Phase II clinical trials of ispinesib. A manuscrip
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:6/30/2015)... -- Today, UBM China, a wholly owned subsidiary of ... Exhibition Co., Ltd. to jointly run the Health Expo ... concurrently with CWMEE 2016. This cooperation ... MEDTEC China and DENTECH China, and fills its blank ... also another concrete cooperative project in Chengdu ...
(Date:6/30/2015)... 2015  July 4 th is this weekend, a ... spirit and people behind it. To help honor our current ... USA Medical Card, a leading provider of ... that empower independence for our disabled military veterans, police, firemen, ... afford their prescriptions. "Due to USA ...
(Date:6/30/2015)... N.C. , June 30, 2015  Marken, the ... to the life sciences industry, has been granted permission ... patient shipment of clinical drug product in Korea.  This ... South Korea to continue receiving their clinical ... System (MERS). The emergency was caused by ...
Breaking Medicine Technology:UBM Joins Chengdu Tianyi to Hold CWMEE 2016 2UBM Joins Chengdu Tianyi to Hold CWMEE 2016 3Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Marken Delivers Direct To Patients During MERS Outbreak 2Marken Delivers Direct To Patients During MERS Outbreak 3
... - VASTox plc (AIM: VOX), a leading,UK biotechnology ... of £400,000 by the Welsh Development Agency,(”WDA”) under ... 12 months, will support the research and development,work ... the unique skills and expertise of its scientists,based ...
... 2007 /PRNewswire-USNewswire/ -- The,following statement may be attributed ... Medical Research (CAMR): , "In the face of ... the stroke of his veto pen deliberately to ... well as endanger,the future health and well being ...
Cached Medicine Technology:Vastox Awarded £400,000 Grant to Support R&D at,Carbohydrate Chemistry Facility 2Vastox Awarded £400,000 Grant to Support R&D at,Carbohydrate Chemistry Facility 3President Bush Ignores America's Plea for Support of Stem Cell,Research 2
(Date:7/1/2015)... CA (PRWEB) , ... July 01, 2015 , ... ... returned to the Northbound team as Director of Referral Relations. , Emily ... including Northbound’s Collegebound, where she designed and implemented unique academic curriculum for clients ...
(Date:7/1/2015)... ... July 01, 2015 , ... These ... to case management, placement, sober companionship and delivery to wilderness therapy or treatment ... with and transporting clients with anxiety, ADHD, autism spectrum disorders, eating disorders, severe ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... communities of southeast Alabama, southwest Georgia and the Florida Panhandle, the regional ... its primary secure text messaging and clinical communications workflow solution provider. TelmedIQ, ...
(Date:7/1/2015)... FL (PRWEB) , ... July 01, 2015 , ... Nutritional ... range of nutritional and beauty products, recently attended the 2015 ECRM Diet, Vitamin & ... connections in the retail industry. The ECRM trade show allows companies the ...
(Date:7/1/2015)... ... July 01, 2015 , ... Foot and Ankle Specialists of the Mid-Atlantic, ... in the annual Howard County Family Wellness Day event at Centennial Park on June ... screenings, activities for children, free workout demonstrations, and more. Drs. Becker and Friske ...
Breaking Medicine News(10 mins):Health News:Northbound Treatment Services Welcomes Emily Orrick as Director of Referral Relations 2Health News:All Kinds of Therapy – Announces New Partnership Feature, Therapeutic Experts 2Health News:Southeast Alabama Community Health System Chooses TelmedIQ to Meet Secure Text Messaging Challenges for Healthcare 2Health News:NPI Meets With Top Retail Figures at ECRM Conference 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Promotes Healthy Living 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Promotes Healthy Living 3
... , EMERYVILLE, Calif., Sept. 3 Bionovo, Inc. ... results from the phase 2 clinical trial of their lead drug candidate ... European Society for Gynecology (EGS) in Rome, Italy. , ... evaluate the safety and efficacy of two doses of Menerba versus placebo. ...
... , , , ... ISIS ), the leader in antisense therapeutics, today announced that management ... Conference on Wednesday, September 9, 2009, at 11:30 a.m. ET at the ... webcast of the presentation will be available on the "Investors & Media" ...
... , , NEW YORK, Sept. ... Manhattan headquartered medical technology company testing its proprietary treatment method for ... signed a three-year lease with the option to buy on a ... plans to locate manufacturing of its Percutaneous Hepatic Perfusion (PHP(TM)) System. ...
... , ... Coker Studies Personality Traits along with Gender and Generational Differences , ... Alpharetta, GA (Vocus) September 3, 2009 ... linked to dominant personality traits? Jackson & Coker has begun a year-long research ...
... , , LOS ANGELES, ... Angeles-based manufacturer of BPA-free baby bottles that provide a safe ... chemical currently banned in Canada, Minnesota, Connecticut and under scrutiny ... California Assembly members to support the Toxics-Free Babies and ...
... , , JACKSONVILLE, Fla., Sept. 2 ... under a year by March of 2009, Linda Quirk of Run7on7.com fame ... first woman to complete the 4 Deserts - a grueling series of ... a continuation of her global efforts to raise funds and awareness for ...
Cached Medicine News:Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 2Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 3Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 4Health News:Isis Pharmaceuticals to Present at Thomas Weisel Partners' Healthcare Conference 2009 2Health News:Delcath Establishes Queensbury, NY Operations Facility 2Health News:Delcath Establishes Queensbury, NY Operations Facility 3Health News:Physicians' Personalities Provide Clues Regarding Job Satisfaction 2Health News:Physicians' Personalities Provide Clues Regarding Job Satisfaction 3Health News:Physicians' Personalities Provide Clues Regarding Job Satisfaction 4Health News:BPA-Free Baby Bottle Manufacturer Green to Grow Urges Public to Demand Support for California's Toxics-Free Babies and Toddlers Act (SB 797) 2Health News:BPA-Free Baby Bottle Manufacturer Green to Grow Urges Public to Demand Support for California's Toxics-Free Babies and Toddlers Act (SB 797) 3Health News:BPA-Free Baby Bottle Manufacturer Green to Grow Urges Public to Demand Support for California's Toxics-Free Babies and Toddlers Act (SB 797) 4Health News:56 Year-Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts(TM) in Under a Year 2Health News:56 Year-Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts(TM) in Under a Year 3
The Meridian Microruptor V Nd: YAG laser system is indicated for posterior capsulotomy, peripheral iridotomy, and pupillary membranectomy procedures....
... effective method for determining color vision abnormalities ... which can be applied to many psychological ... consists of four trays containing a total ... have incremental hue variation on one side ...
... consists of a Matching Card, three HRR symbol ... prepare a child for subsequent HRR 4th Edition ... the test. For the youngest patients, the parents ... learn the concept of matching and become familiar ...
... from Richmond Products includes the four demonstration plates, ... series for a total of 24 plates. Each ... easy and clean page selection. The test also ... a laminated copy of the score sheet. The ...
Medicine Products: